Fluorouracil

• Safety, tolerability, and efficacy of mFOLFIRINOX ±BNT321 as adjuvant therapy following curative resection in patients with pancreatic adeno… Not authorised
  2023-506014-47-00 Phase I/II 4 countries BioNTech SE
• PRODIGE 113 (FFCD 2314) – REWENEC – 01 STUDY Randomized trial of FOLFIRI + Zimberelimab + Domvanalimab vs FOLFIRI with a hybrid synthetic co… Not authorised
  2024-519922-19-00 Phase II 1 country Hospices Civils De Lyon
• Neo-adjuvant intraperitoneal chemotherapy (irinotecan) and systemic chemotherapy (mFOLFOX4-bevacizumab) prior to CRS-HIPEC for patients with… Pending
  2024-512318-16-00 Phase II 1 country Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC)
• A study to evaluate the efficacy of oxaliplatin- or gemcitabine-based chemotherapy after allocation by standard criteria or by genetic marke… Pending
  2024-514682-19-00 Phase III 2 countries Universitaetsklinikum Heidelberg AöR
• Phase II study of Durvalumab (MEDI4736) plus Total Neoadjuvant Therapy (TNT) in locally advanced rectal cancer (The DUREC trial) Pending
  2024-515240-24-00 Phase II 1 country Grupo Espanol Multidisciplinar En Cancer Digestivo
• Randomized trial of standard chemotherapy alone or combined with atezolizumab as adjuvant therapy for patients with stage III colon cancer a… Pending
  2024-517269-18-00 Phase III 1 country AIO-Studien gGmbH; National Cancer Institute
• Maintenance With OSE2101 Plus FOLFIRI, or FOLFIRI After FOLFIRINOX-based Induction Therapy in Locally Advanced or Metastatic Pancreatic Duct… Pending
  2024-518139-12-00 Phase II 1 country Association Gercor
• BALLAD Belgium - A trial to evaluate the potential benefit of adjuvant chemotherapy for small bowel adenocarcinoma. The Belgian component of… Pending
  2024-518349-85-01 Phase III 1 country Groupe Belge D'Oncologie Digestive
• Chemo-immunotherapy before and after surgery for peritoneal metastases of large bowel cancer. Pending
  2024-518570-13-00 Phase II/III 2 countries Catharina Ziekenhuis Stichting
• A randomized phase III trial of short-course versus long-course pre-operative chemotherapy with mFOLFIRINOX or PAXG regimen for stage I-III … Pending
  2024-519031-42-00 Phase III 1 country Associazione Italiana Per Lo Studio Del Pancreas
• PRODIGE 104 – NEOPREDICT A multicenter phase II trial using transcriptomic signatures to personalize neoadjuvant chemotherapy for patients … Pending
  2024-519753-11-00 Phase II 1 country Fondation Franc.Cancerologie Digestive
• A trial to learn how well sonesitatug vedotin and capecitabine with or without rilvegostomig work and how safe they are in adults with cance… Pending
  2024-519787-40-00 Phase III 8 countries AstraZeneca AB
• Personalizing chemotherapy selection after surgery for patients with stage III colorectal cancer using a blood test Pending
  2025-521045-24-00 Phase III 2 countries Unicancer
• A biomarker enrichment trial of anti-EGFR agents in patients with advanced colorectal cancer (aCRC) with wild-type RAS and right primary tum… Pending
  2025-521209-42-00 Phase IV 3 countries Fondazione GONO G.I.
• Study evaluating two treatment strategies for rectal cancer in patients ≥75 years old Pending
  2025-521619-37-00 Phase III 1 country Unicancer
• Impact of Biweekly and Triweekly Dosing Regimens Pending
  2025-522305-38-00 Phase II 1 country University Of Pecs
• Use of the chemotherapy FOLFIRI and cetuximab if given with treatment breaks or continuously in patients with newly diagnosed metastatic col… Pending
  2025-522377-12-00 Phase III 1 country Charite Universitaetsmedizin Berlin KöR
• Molecularly Tailored Therapy versus Standard Care in Advanced Pancreatic Cancer Pending
  2025-522431-34-00 Phase II 1 country Region Hovedstaden
• A Study to Assess Intravenous (IV) Telisotuzumab Adizutecan in Combination with Fluorouracil, Folinic Acid, and Oxaliplatin (FOLFOX) Compare… Pending
  2025-522563-15-00 Phase II/III 1 country AbbVie Deutschland GmbH & Co. KG
• Study of the combination of the drug ASP-1929 and light illumination with the device PIT690 laser system in addition with pembrolizumab vers… Pending
  2025-523017-28-00 Phase III 1 country Rakuten Medical Inc.
• A Randomized, Double-Blind, Phase 3 Study of Standard-of-Care Chemotherapy and Bevacizumab With or Without INCA33890 in the First-Line Treat… Pending
  2025-523735-19-00 Phase III 10 countries Incyte Corp.
• Liver-directed chemotherapy after surgery of liver metastases of colorectal cancer in patients with high risk of recurrence of their disease… Pending
  2025-523913-27-00 Phase III 1 country Unicancer
• Paclitaxel plus ramucirumab and tislelizumab as switch maintenance versus continuation of chemotherapy and tislelizumab in patients with adv… Pending
  2025-524048-36-00 Phase III 3 countries Fondazione GONO G.I.
• A Randomized, Double-Blind, Phase 3 Study of Chemotherapy With or Without INCB161734 in Previously Untreated, KRAS G12D–Mutated Metastatic P… Pending
  2025-525009-18-00 Phase III 11 countries Incyte Corp.

Showing 1–24 of 231 trials